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Background: The EXCELLA BD trial is a prospective multicenter randomized (3:1) controlled study of novolimus-eluting stents (NES) with 
bioabsorbable polymer (DESyne BD, Elixir Medical Corp.) for the treatment of de novo coronary lesions compared with Endeavor zotarolimus-eluting 
stents (ZES). The aim of this study was to compare the vessel response between NES and ZES as assessed by IVUS.
Methods: The EXCELLA BD IVUS cohort consisted of 72 patients (NES: 54, ZES: 18). Volume index (VI: volume/length, mm3/mm) was measured for 
vessel, lumen, plaque, stent, and neointima. Neointimal obstruction was obtained as neointimal volume divided by stent volume (%). Cross-sectional 
narrowing (CSN) was calculated as neointimal area divided by stent area (%).
Results: Minimum lumen area (MLA) at baseline was similar in the 2 groups. At follow-up, NES showed a significantly larger MLA with smaller 
late lumen area loss, neointimal obstruction and maximum CSN, resulting in significantly lower incidence of IVUS-defined restenosis (maximum 
CSN>50%) compared to ZES. Late incomplete stent apposition was observed 2 cases in NES; however neither was associated with positive vessel 
remodeling.
Conclusions: Detailed IVUS analysis confirmed significantly greater neointimal suppression and no evidence of adverse local vessel response in 
NES with bioabsorbable polymer as compared to ZES up to 6 months. Longer clinical follow-up of these patients is ongoing to confirm the durability 
of this novel stent technology.
IVUS volumetric analysis results
NES ZES P
MLA at baseline (mm2) 6.1±2.0 5.6±2.1 0.543
MLA at follow-up (mm2) 5.5±2.1 4.1±1.5 0.025
Late lumen area loss (mm2) 0.3±0.7 1.6±1.8 0.003
Neointimal obstruction (%) 3.6±4.2 20.7±14.2 <0.001
Maximum CSN (%) 12.1±12.4 37.5±20.1 <0.001
Stents with maximum CSN>50% (%) 2.9 37.5 <0.001
Δ Vessel volume (mm3/mm) -0.3±1.3 0.3±0.6 0.192
Late incomplete stent apposition (%) 5.7 0 0.329
